The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-basedtopicalformulations for reducing oxidative stress and inflammation.
The conversation discusses creating a personalized topical treatment for hair loss, with ingredients like finasteride, minoxidil, tretinoin, melatonin, caffeine, and others. Users share their ideal formulations, including combinations of minoxidil, finasteride, tretinoin, adenosine, and other compounds, while also discussing the importance of managing inflammation.
Liposomal formulations of finasteride and minoxidil may enhance drug delivery to the skin and hair follicles more effectively than traditional solutions, potentially improving treatment outcomes. However, more human clinical trials are needed to confirm these benefits.
The conversation discusses the link between seborrheic dermatitis, acne, and male pattern baldness, suggesting that DHT may cause both skin conditions and hair loss. Treatments mentioned include RU58841, finasteride, dutasteride, minoxidil, Nizoral shampoo, and other topical anti-androgens.
A sugar gel containing 2-deoxy-D-ribose has shown promising hair regrowth results in mice, comparable to Minoxidil. Users are discussing the potential to buy and try this compound themselves.